Real-world data on healthcare resource consumption and costs before and after kidney transplantation.
dialysis
economics
kidney disease
preventive healthcare
registry/registry analysis
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
12
04
2019
revised:
15
09
2019
accepted:
30
09
2019
pubmed:
7
10
2019
medline:
22
9
2020
entrez:
7
10
2019
Statut:
ppublish
Résumé
End-stage renal disease (ESRD) is increasing worldwide as a consequence of population aging and increasing chronic illness. Treatment consists mostly of dialysis and kidney transplantation (KTx), and KTx offers advantages for life expectancy and long-term cost reductions compared with dialysis. This study uses the administrative database of the Lombardy Region to analyze the costs of a cohort of patients with ESRD receiving KTx, covering a time period of 24 months before transplant to 12 months after. During 2011, 276 patients underwent kidney transplantation (8.7% preemptive and 91.3% non-preemptive). In the period before transplantation, the main cost driver was dialysis (66.6% for the period from -24 to -12 months and 73.8% for the period from -12 to 0 months), while in the 12 months after KTx, the most relevant cost was surgery. The total cost -24 to -12 months pre-KTx was 35 049.2€; the cost -12 to 0 months was 36 745.9€; and the cost 12 months after KTx was 43 805.8€. Non-preemptive patients showed much higher costs both pre- and post-KTx than preemptive patients. This study highlights how KTx modifies the resource consumption and costs composition of patients with ESRD vs those undergoing dialysis treatment and how KTx may be economically beneficial, especially preemptive intervention.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13728Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet. 2001;357(9268):1601-1608.
Atkins RC. The epidemiology of chronic kidney disease. Kidney Int. 2005;67(suppl):S14-S18.
Hamer RA, MeguidEkNahas A. The burden of chronic kidney disease. BMJ. 2006;332:563-564.
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
Centers for Disease Control and Prevention. Prevalence of chronic kidney disease and associated risk factors-United States, 1999-2004. MMWR Morb Mortal Wkly Rep. 2007;56(8):161-165.
Meisinger C, Döring A, Löwel H, KORA Study Group. Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. Eur Heart J. 2006;27(10):1245-1250.
Sakhuja V, Sud K. End-stage renal disease in India and Pakistan: Burden of disease and management issues. Kidney Int. 2003;83:S115-S118.
Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342(9):605-612.
Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int. 1996;50(1):235-242.
Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23):1725-1730.
Yen EF, Hardinger K, Brennan DC, et al. Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant. Am J Transplant. 2004;4(10):1703-1708.
Perović S, Janković S. Renal transplantation vs hemodialysis: cost-effectiveness analysis. Vojnosanit Pregl. 2009;66(8):639-644.
Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making. 2002;22(5):417-430.
Il valore del trapianto. Un'analisi empirica dei consumi sanitari e dei costi dei trapiantati di Rene in Italia. http://www.forumtrapiantitalia.it/2013-censis/SINTESI_CENSIS_TRAPIANTI.pdf. Accessed February 25, 2016.
Cavallo MC, Sepe V, Conte F, et al. Cost-effectiveness of kidney transplantation from DCD in Italy. Transplant Proc. 2014;46(10):3289-3296.
Ashby VB, Kalbfleisch JD, Wolfe RA, Lin MJ, Port FK, Leichtman AB. Geographic variability in access to primary kidney transplantation in the United States, 1996-2005. Am J Transplant. 2007;7(Suppl 1):1412-1423.
Meier-Kriesche HU, Port FK, Ojo AO, et al. Effect of waiting time on renal transplant outcome. Kidney Int. 2000;58:1311-1317.
US Renal Data System: USRDS 2006 Annual Data Report. http://www.usrds.org/adr_2006.htm. Accessed June 19, 2007.
Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes. Transplantation. 2002;74(10):1377-1381.
Kasiske BL, Snyder JJ, Matas MD, et al. Pre-emptive kidney transplantation: the advantage and the advantaged. J Am SocNephrol. 2002;13:1358-1366.
Garcia GG, Harden P, Chapman J, For the World Kidney Day Steering Committee 2012. The Global role of kidney transplantation. J Nephropathol. 2012;1(2):69-76.
Nassir BA, Dean CE, Li S, et al. Variation in cost and quality in kidney transplantation. Transplantation. 2015;99(10):2150-2157.
Sánchez-Escuredo A, Alsina A, Diekmann F, et al. Economic analysis of the treatment of end-stage renal disease treatment: living-donor kidney transplantation versus hemodialysis. Transplant Proc. 2015;47(1):30-33.
Chaib-Eddour D, Chaib-Eddour H, Malaise J, Mourad M, Squifflet JP. Cost of renal transplant in Belgium. Transplant Proc. 2005;37(6):2819-2820.
Hagenmeyer EG, Häussler B, Hempel E, et al. Resource use and treatment costs after kidney transplantation: impact of demographic factors, comorbidities, and complications. Transplantation. 2004;77(10):1545-1550.
International Classification of Diseases (ICD). 9th Revision, Basic Tabulation List with Alphabetic Index. Geneva, Switzerland: World Health Organization; 1978.
Gavrielov-Yusim N, Friger M. Use of administrative medical databases in population-based research. J Epidemiol Community Health. 2014;68:283-287.
Wang Z, Ho PWH, Choy MTH, Wong ICK, Brauer R, Man KKC. Advances in epidemiological methods and utilization of large databases: a methodological review of observational studies on central nervous system drug use in pregnancy and central nervous system outcomes in children. Drug Saf. 2019;42(4):499-513. https://orcid.org/10.1007/s40264-018-0755-y
Cainzos-Achirica M, Capdevila C, Vela E et al Individual income, mortality and healthcare resource use in patients with chronic heart failure living in a universal healthcare system: a population-based study in Catalonia, Spain. Int J Cardiol. 2018;S0167-S5273(18):33690-33698.
Pontoriero G, Pozzoni P, Vecchio LD, et al. International study of health care organization and financing for renal replacement therapy in Italy: an evolving reality. Int J Health Care Finance Econ. 2007;7:201-215.
Zoccali C, Kramer A, Jager KJ. Chronic kidney disease and end-stage renal disease-a review produced to contribute to the report ‘the status of health in the European Union: towards a healthier Europe’. NDT Plus. 2010;3(213-312):224.
Janjua HS, Hains DS, Mahan JD. Kidney transplantation in the United States: economic burden and recent trends analysis. Prog Transplant. 2013;23(1):78-83.
Blotière PO, Tuppin P, Weill A, Ricordeau P, Allemand H. [The cost of dialysis and kidney transplantation in France in 2007, impact of an increase of peritoneal dialysis and transplantation]. Nephrol Ther. 2010; 6(4):240-247.
Chamberlain G, Baboolal K, Bennett H, et al. The economic burden of posttransplant events in renal transplant recipients in Europe. Transplantation. 2014;97(8):854-861.
Haut ER, Pronovost PJ, Schneider EB. Limitations of administrative databases. JAMA. 2012;307(24):2589-2590.
Schneeweiss S, Avorn J. A review of uses of healthcare utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323-337.
Harpe SE. Using secondary data sources for pharma-coepidemiology and outcomes research. Pharmacotherapy. 2009;29(2):138-153.